Marc E. Rothenberg

Last updated
Marc E. Rothenberg
Born (1961-01-17) January 17, 1961 (age 63) [1]
Forest Hills, NY
EducationBrandeis University; Harvard Medical School
TitleProfessor of Pediatrics;

Director, Division of Allergy and Immunology at Cincinnati Children's Hospital Medical Center;

Director, Cincinnati Center for Eosinophilic Disorders

Contents

Marc E. Rothenberg (born 1961) is an American physician-scientist who has made significant contributions to the fields of allergy, gastroenterology, and immunology. He is currently a Professor of Pediatrics, at Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine, the Director of the Division of Allergy and Immunology, the Director of the Cincinnati Center for Eosinophilic Disorders, [2] and the principal investigator of the Consortium of Eosinophilic Disease Researchers (CEGIR) [3] as part of the Rare Disease Clinical Research Network of the National Institute of Health. [4] Rothenberg's research is focused on eosinophilic gastrointestinal diseases. [5]

Early life and education

Rothenberg was born in New York City in 1961. He received his Bachelor of Arts degree in Biochemistry and Chemistry from Brandeis University in 1983. His undergraduate years were influences by the renowned biochemist Professor William P. Jencks, who was Rothenberg’s early research mentor. [6] He went on to earn his medical degree and PhD in Immunology from Harvard Medical School in 1990, conducting research under the mentorship of Professor K. Frank Austen. [6] He completed his residency in pediatrics at Boston Children's Hospital and his fellowship in Allergy and Immunology and Hematology at Boston Children’s Hospital and the Dana Farber Cancer Institute. [2]

Career

Rothenberg began his career as a faculty member at the University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center in 1996, where he has since remained. [2] Rothenberg established the Cincinnati Center for Eosinophilic Disorders, a center focused on eosinophilic diseases. [7]

In 2016, Rothenberg was the first recipient of the Denise and Dave Bunning Chair for Allergy and Immunology. [8]

Rothenberg is also the current Director of the NIH-sponsored Consortium of Eosinophilic Gastrointestinal Disease Researchers, part of the Rare Diseases Clinical Research Network. [3] In 2021, he was elected Co-Chair of the RDCRN. [9]

Research

The Rothenberg CURED Laboratory at Cincinnati Children's Hospital Medical Center conducts research focused on the molecular analysis of allergic inflammation, particularly the pathogenesis of eosinophilic gastrointestinal disorders. [10] His research is credited with elucidating the mechanism of eosinophilia, including the identification of key checkpoints that are central targets for therapeutic intervention. These targets have been translated into developed clinical products. Rothenberg's research has included key proof-of-principle studies that provided the bases for a new class of drugs, anti-eosinophil therapeutics, as well as the first FDA approved drug for eosinophilic esophagitis.

Awards and honors

Rothenberg has been recognized for his contributions to science and medicine with numerous honors and awards, including the American Academy of Allergy, Asthma, and Immunology (AAAAI) Distinguished Scientist Award, [11] the National Institutes of Health (NIH) Merit Award, [12] the E. Mead Johnson Award from the Society of Pediatric Research, [13] and the Paul Ehrlich Award [14] from the International Eosinophil Society. Rothenberg was also recognized as a Highly Cited Researcher in 2018 (Clarivate Analytics). [15] He is an elected member of the American Society for Clinical Investigation, [16] the Association of American Physicians and the National Academy of Medicine. [17] [18] In 2023, Rothenberg was awarded the Daniel Drake Medal for his impact on the field of Allergy and Immunology. [19]

Publications

Rothenberg has authored and co-authored over 500 peer-reviewed articles. [20] [21]

Related Research Articles

<span class="mw-page-title-main">Eosinophil</span> Variety of white blood cells

Eosinophils, sometimes called eosinophiles or, less commonly, acidophils, are a variety of white blood cells and one of the immune system components responsible for combating multicellular parasites and certain infections in vertebrates. Along with mast cells and basophils, they also control mechanisms associated with allergy and asthma. They are granulocytes that develop during hematopoiesis in the bone marrow before migrating into blood, after which they are terminally differentiated and do not multiply.

<span class="mw-page-title-main">Hypereosinophilic syndrome</span> Unexplained chronic eosinophila

Hypereosinophilic syndrome is a disease characterized by a persistently elevated eosinophil count in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow.

<span class="mw-page-title-main">Eosinophilic esophagitis</span> Allergic inflammatory condition of the esophagus

Eosinophilic esophagitis (EoE) is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. In healthy individuals, the esophagus is typically devoid of eosinophils. In EoE, eosinophils migrate to the esophagus in large numbers. When a trigger food is eaten, the eosinophils contribute to tissue damage and inflammation. Symptoms include swallowing difficulty, food impaction, vomiting, and heartburn.

<span class="mw-page-title-main">Eosinopenia</span> Medical condition

Eosinopenia is a condition where the number of eosinophils, a type of white blood cell, in circulating blood is lower than normal. Eosinophils are a type of granulocyte and consequently from the same cellular lineage as neutrophils, basophils, and mast cells. Along with the other granulocytes, eosinophils are part of the innate immune system and contribute to the defense of the body from pathogens. The most widely understood function of eosinophils is in association with allergy and parasitic disease processes, though their functions in other pathologies are the subject of ongoing research. The opposite phenomenon, in which the number of eosinophils present in the blood is higher than normal, is known as eosinophilia.

Founded in 1943, the American Academy of Allergy, Asthma & Immunology (AAAAI) is a professional medical membership organization of more than 7,000 allergists/immunologists and related professionals around the world with advanced training and experience in allergy, asthma and other immunologic diseases. The Academy is dedicated to the advancement of the knowledge and practice of allergy, asthma and immunology for optimal patient care.

Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.

<span class="mw-page-title-main">Eosinophilic gastroenteritis</span> Medical condition

Eosinophilic gastroenteritis, also known as eosinophilic enteritis, is a rare and heterogeneous condition characterized by patchy or diffuse eosinophilic infiltration of gastrointestinal (GI) tissue, first described by Kaijser in 1937. Presentation may vary depending on location as well as depth and extent of bowel wall involvement and usually runs a chronic relapsing course. It can be classified into mucosal, muscular and serosal types based on the depth of involvement. Any part of the GI tract can be affected, and isolated biliary tract involvement has also been reported. The stomach is the organ most commonly affected, followed by the small intestine and the colon.

<span class="mw-page-title-main">Thomas Platts-Mills</span> British academic

Thomas Alexander Evelyn Platts-Mills, FRS, son of British member of parliament and barrister John Platts-Mills, is a British allergy researcher and director of the Division of Allergy and Clinical Immunology at the University of Virginia School of Medicine.

An aeroallergen is any airborne substance, such as pollen or spores, which triggers an allergic reaction.

Hans Dieter Ochs, is an immunologist and pediatrician. He is Professor of Pediatrics, Division of Immunology, Department of Pediatrics, University of Washington School of Medicine, Seattle.

The Rare Diseases Clinical Research Network (RDCRN) is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). The RDCRN is designed to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment, and data sharing. Through the RDCRN consortia, physician scientists and their multidisciplinary teams work together with patient advocacy groups to study more than 200 rare diseases at sites across the nation.

The Rare Diseases Clinical Research Network (RDCRN) Contact Registry is a patient contact registry started in 2004 and sponsored by the National Institutes of Health (NIH). The RDCRN Contact Registry collects and stores the contact information of people who want to participate in RDCRN-sponsored research or learn more about RDCRN research. It connects patients with researchers in order to advance rare disease research.

<span class="mw-page-title-main">Dupilumab</span> Drug used to treat allergic diseases

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis, prurigo nodularis and COPD.

<span class="mw-page-title-main">Kari Nadeau</span> American Physician and scientist

Kari C. Nadeau is the Chair of the Department of Environmental Health at Harvard School of Public Health and John Rock Professor of Climate and Population Studies. She is adjunct professor at Stanford University in the Department of Pediatrics and the co-chair of the Medical Societies Consortium for Climate Change and Health. She practices Allergy, Asthma, Immunology in children and adults. She has published over 400+ papers, many in the field of climate change and health. Her team focuses on quantifying health outcomes of solutions as they pertain climate change mitigation and adaptation at the local, regional, country, and global levels. Dr. Nadeau, with a team of individuals and patients and families, has been able to help major progress and impact in the clinical fields of immunology, infection, asthma, and allergy. Dr. Nadeau is a member of the National Academy of Medicine and the U.S. EPA Children’s Health Protection Committee.

Gail Ina Greenberg Shapiro was an American pediatric allergist based in Seattle. She was a faculty member at the University of Washington School of Medicine. In 2001, she became the first democratically elected president of the American Academy of Allergy, Asthma, and Immunology (AAAAI).

Familial eosinophilia is a rare congenital disorder characterized by the presence of sustained elevations in blood eosinophil levels that reach ranges diagnostic of eosinophilia or, far more commonly, hypereosinophilia. Although high eosinophil levels are associated with certain diseases and thought to contribute to the tissue destruction found in many other eosinophilia-related diseases, clinical manifestations and tissue destruction related to the eosinophilia in familial eosinophilia is uncommon: this genetic disease typically has a benign phenotype and course compared to other congenital and acquired eosinophilic diseases.

<span class="mw-page-title-main">Mariana Castells</span> Spanish-American allergist

Mariana Castells is a Spanish-American allergist who focuses on mast cell diseases, including mastocytosis, mast cell activation syndrome and hereditary alpha tryptasimia. Mastocytosis is a rare disease with limited treatment options. Castells works at Brigham and Women's Hospital in Massachusetts in the Department of Allergy, Rheumatology, and Immunology and at the Dana Farber Cancer Institute. She is also a professor of medicine at Harvard Medical School.

Cezmi Akdis is a medical researcher in the field of immunology. He is director of the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland and the editor in chief of the journal Allergy.

Lirentelimab is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). In a randomized clinical trial, lirentelimab was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis. Adverse reactions include infusion reactions, which are mild to moderate and typically occur following the first infusion.

Anil Mishra is an Indian doctor, scientist and professor of Medicine. He directs the Eosinophilic Disorder Centre at Tulane School of Medicine.

References

  1. ↑ "Rothenberg, Marc E., 1961- - LC Linked Data Service: Authorities and Vocabularies | Library of Congress, from LC Linked Data Service: Authorities and Vocabularies (Library of Congress)". Library of Congress. Retrieved 1 July 2022.
  2. 1 2 3 "Marc E. Rothenberg, MD, PhD". www.cincinnatichildrens.org. Retrieved 2021-12-16.
  3. 1 2 "Scientist Spotlight: Marc Rothenberg Leads Eosinophilic Collaboration and Research to New Discoveries". Rare Diseases Clinical Research Network. Retrieved 2021-12-16.
  4. ↑ "Rare Diseases Clinical Research Network".
  5. ↑ "Rothenberg CURED Lab". Cincinnati Children's Hospital. Retrieved 2021-12-16.
  6. 1 2 "Rothenberg Named to National Academy of Medicine". 17 October 2022.
  7. ↑ "Eosinophilic Gastrointestinal Disorders | Rothenberg Laboratory Current Projects". www.cincinnatichildrens.org. Retrieved 2021-12-16.
  8. ↑ "Marc Rothenberg Receives First Bunning Chair Cincinnati Children's". www.cincinnatichildrens.org. Retrieved 2021-12-16.
  9. ↑ "RDCRN Announces New 2021 Network Steering Committee Leadership". Rare Diseases Clinical Research Network. Retrieved 2021-12-16.
  10. ↑ "Eosinophilic Gastrointestinal Disorders | Rothenberg Laboratory Current Projects". www.cincinnatichildrens.org. Retrieved 2022-04-30.
  11. ↑ "2023 AAAAI Honorary Award Recipients".
  12. ↑ "Doctor at Cincinnati Children's receives prestigious NIH MERIT Award to extend research of eosinophilic gastrointestinal disorders". www.cincinnatichildrens.org. Retrieved 2021-12-16.
  13. ↑ "Past Award Recipients – Society for Pediatric Research" . Retrieved 2022-04-30.
  14. ↑ "Dr. Rothenberg received the Paul Ehrlich Lectureship Award". Rare Diseases Clinical Research Network. Retrieved 2022-03-31.
  15. ↑ "Clarivate Analytics Highly Cited Researchers 2018-Congratulations to Dr Marc Rothenberg! Edward L. Pratt Research Library". prattlibrary.cchmc.org. Retrieved 2021-12-16.
  16. ↑ "The American Society for Clinical Investigation Directory".
  17. ↑ "About the National Academy of Medicine, Class of 2022". National Academy of Medicine.
  18. ↑ "Rothenberg Named to National Academy of Medicine". 17 October 2022.
  19. ↑ "Four to receive 2023 Daniel Drake Medals from the College of Medicine". 6 April 2023.
  20. ↑ "My Bibliography - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2022-04-30.
  21. ↑ "Google Scholar, Marc E. Rothenberg, MD, PhD Profile".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.